Lv52
980 积分 2026-08-27 加入
Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
24秒前
待确认
International Federation for the Surgery of Obesity statement on metabolic bariatric surgery after pharmacotherapy-induced weight loss in clinical obesity
1分钟前
已完结
Beyond a singular focus on GLP-1: why we need a new nomenclature now
3分钟前
已完结
Is biased agonism helpful in the treatment of obesity with the GLP-1 receptor analogues?
6分钟前
已完结
Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial
9分钟前
已完结
Rethinking obesity through the lens of genetics, environment and differential life circumstances
12分钟前
已完结
Ecnoglutide, a biased GLP-1 receptor agonist as a potential new player for type 2 diabetes management?
13分钟前
已完结
Cardiovascular risk in type 1 versus type 2 diabetes
14分钟前
已完结
Growing evidence for semaglutide efficacy in Asian adults with obesity
15分钟前
已完结
Understanding the mechanism of prediabetes remission in young people
19分钟前
已完结
皖公网安备34019202002308
